Nonetheless, future work employing next-generation inhibitors with greater selectivity, or complementary genetic approaches, will be critical to confirm PRMT1-specific mechanisms and refine its therapeutic potential in MM. This evidence concerns the gene PRMT1 and Miyoshi myopathy.